Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for previously treated advanced hepatocellular
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated advanced hepatocellular carcinoma. Following on from advice received from the company NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
 
Status Suspended
Process STA 2018
ID number 1458

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
29 March 2019 Suspended, As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated advanced hepatocellular carcinoma. Following on from advice received from the company NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
28 September 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated advanced hepatocellular carcinoma. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late April 2019.
15 August 2018 - 13 September 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
21 March 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance